Mineralocorticoid receptor antagonists - pharmacodynamics and pharmacokinetic differences

被引:37
作者
Yang, Jun [1 ,2 ]
Young, Morag J. [1 ,2 ]
机构
[1] Hudson Inst Med Res, Clayton, Vic, Australia
[2] Monash Univ, Clayton, Vic, Australia
关键词
SELECTIVE ALDOSTERONE BLOCKER; LEFT-VENTRICULAR DYSFUNCTION; RANDOMIZED CLINICAL-TRIAL; HEART-FAILURE; DIABETIC-NEPHROPATHY; HIGHLY POTENT; BAY; 94-8862; EPLERENONE; SPIRONOLACTONE; HYPERTENSION;
D O I
10.1016/j.coph.2016.02.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mineralocorticoid receptor antagonists (MRAs) are best known as potassium-sparing diuretics due to their blockade of aldosterone action in renal epithelial tissues. They are also beneficial for the treatment of heart failure, primarily due to effects in non-epithelial tissues. Currently there are only two steroidal MRAs that have been approved for use; spironolactone (and its active metabolite canrenone) and eplerenone. However, the search is on for novel generations of MRAs with increased potency and tissue selectivity. A number of novel non-steroidal compounds are in preclinical and early development, with one agent moving to phase Ill trials. The development of these agents and the mechanisms for their pharmacologic superiority compared to earlier generations of MRAs will be discussed in this review.
引用
收藏
页码:78 / 85
页数:8
相关论文
共 63 条
  • [1] Role of 11β-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries
    Alzamora, R
    Michea, L
    Marusic, ET
    [J]. HYPERTENSION, 2000, 35 (05) : 1099 - 1104
  • [2] Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
    Amazit, Larbi
    Le Billan, Florian
    Kolkhof, Peter
    Lamribet, Khadija
    Viengchareun, Say
    Fay, Michel R.
    Khan, Junaid A.
    Hillisch, Alexander
    Lombes, Marc
    Rafestin-Oblin, Marie-Edith
    Fagart, Jerome
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (36) : 21876 - 21889
  • [3] Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
    Arai, Kiyoshi
    Homma, Tsuyoshi
    Morikawa, Yuka
    Ubukata, Naoko
    Tsuruoka, Hiyoyuki
    Aoki, Kazumasa
    Ishikawa, Hirokazu
    Mizuno, Makoto
    Sada, Toshio
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 761 : 226 - 234
  • [4] Discovery of Novel Cyanodihydropyridines as Potent Mineralocorticoid Receptor Antagonists
    Arhancet, Graciela B.
    Woodard, Scott S.
    Iyanar, Kaliappan
    Case, Brenda L.
    Woerndle, Rhonda
    Dietz, Jessica D.
    Garland, Danny J.
    Collins, Joe T.
    Payne, Maria A.
    Blinn, James R.
    Pomposiello, Silvia I.
    Hu, Xiao
    Heron, Marcia I.
    Huang, Horng-Chih
    Lee, Len F.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (16) : 5970 - 5978
  • [5] Role of Nongenomic Signaling Pathways Activated by Aldosterone During Cardiac Reperfusion Injury
    Ashton, Anthony W.
    Le, Thi Y. L.
    Gomez-Sanchez, Celso E.
    Morel-Kopp, Marie-Christine
    McWhinney, Brett
    Hudson, Amanda
    Mihailidou, Anastasia S.
    [J]. MOLECULAR ENDOCRINOLOGY, 2015, 29 (08) : 1144 - 1155
  • [6] Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
    Baerfacker, Lars
    Kuhl, Alexander
    Hillisch, Alexander
    Grosser, Rolf
    Figueroa-Perez, Santiago
    Heckroth, Heike
    Nitsche, Adam
    Ergueden, Jens-Kerim
    Gielen-Haertwig, Heike
    Schlemmer, Karl-Heinz
    Mittendorf, Joachim
    Paulsen, Holger
    Platzek, Johannes
    Kolkhof, Peter
    [J]. CHEMMEDCHEM, 2012, 7 (08) : 1385 - 1403
  • [7] Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy A Randomized Clinical Trial
    Bakris, George L.
    Agarwal, Rajiv
    Chan, Juliana C.
    Cooper, Mark E.
    Gansevoort, Ron T.
    Haller, Hermann
    Remuzzi, Giuseppe
    Rossing, Peter
    Schmieder, Roland E.
    Nowack, Christina
    Kolkhof, Peter
    Joseph, Amer
    Pieper, Alexander
    Kimmeskamp-Kirschbaum, Nina
    Ruilope, Luis M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (09): : 884 - 894
  • [8] Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases
    Bauersachs, Johann
    Jaisser, Frederic
    Toto, Robert
    [J]. HYPERTENSION, 2015, 65 (02) : 257 - U42
  • [9] BRILLA CG, 1992, J LAB CLIN MED, V120, P893
  • [10] Identification of (R)-6-(1-(4-Cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic Acid, a Highly Potent and Selective Nonsteroidal Mineralocorticoid Receptor Antagonist
    Casimiro-Garcia, Agustin
    Piotrowski, David W.
    Ambler, Catherine
    Arhancet, Graciela B.
    Banker, Mary Ellen
    Banks, Tereece
    Boustany-Kari, Carine M.
    Cai, Cuiman
    Chen, Xiangyang
    Eudy, Rena
    Hepworth, David
    Hulford, Catherine A.
    Jennings, Sandra M.
    Loria, Paula M.
    Meyers, Marvin J.
    Petersen, Donna N.
    Raheja, Neil K.
    Sammons, Matthew
    She, Li
    Song, Kun
    Vrieze, Derek
    Wei, Liuqing
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (10) : 4273 - 4288